Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017

Therapeutic Innovation and Regulatory Science - United States
doi 10.1177/2168479019860122
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Lessons From a Cardiovascular Outcome Trial With Liraglutide in Type 2 Diabetes

Journal of Diabetes Investigation
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2017English

Cardiovascular Outcome Trials of Diabetes Drugs: Lessons Learned

Journal of Clinical Investigation
Medicine
2018English

Impact of Diabetes Duration and Cardiovascular Risk Factors on Mortality in Type 2 Diabetes: The Hoorn Study

European Journal of Clinical Investigation
MedicineBiochemistryClinical Biochemistry
2002English

Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials to the Overall Type 2 Diabetes Population in the United States

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Cardiovascular Outcome Trials in Diabetes: What Have We Learnt?

Trends in Urology & Men's Health
2018English

Initiation of Smoking and Susceptibility to Type 2 Diabetes: A Mendelian Randomization Study

2020English

Hypoglycaemia in Type 2 Diabetes – Clinical Consequences and Impact on Treatment

European Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2010English

Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy